People | December 14, 2023
Moderna Chief Commercial Officer steps down, President to look over pipeline strategy
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
New facility is part of Aptar Pharma’s global expansion program
This acquisition marks Max Healthcare's entry into Lucknow
Express Scripts to add Zepbound to National Preferred Formulary
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
